Drug intelligence / Profile preview

TP-3 (China Pharma Univ.)

Development stage: Preclinical
Lead developer: China Pharmaceutical University

Overview

TP-3 (China Pharma Univ.): sourced facts only. name: "TP-3 shows strong dual inhibitory effects on both tubulin and PARP-1." [PMID:34670362]; target: "TP-3 shows strong dual inhibitory effects on both tubulin and PARP-1." [PMID:34670362]; developer: "School of Life Science and Technology, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing 210009, China." [PMID:34670362]; stage: "In vivo assessment indicates that TP-3 inhibits the growth of MDA-MB-231 xenograft tumors in nude mouse with no notable side effects." [PMID:34670362]

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on TP-3 (China Pharma Univ.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TP-3 (China Pharma Univ.).